Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB1001 biosimilar versus EU-licensed Prolia in postmenopausal osteoporosis
2021-002187-49Phase 3Terminated
- Sponsor
- Eden Biologics, Inc.
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis comparing EB1001 with EU-licensed Prolia (2 arms). Primary endpoint: Percent change in lumbar spine bone mineral density at Month 12. Started Jun 2021; status: terminated.
02
Drugs
EB1001denosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2021-002187-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002187-49.